About Model Medicines
Model Medicines develops potential medicines to treat human disease. It uses artificial intelligence to design drug compounds aimed at biological processes involved in illness.
The company is based in San Diego. Daniel Haders II, Ph.D., is founder and chief executive officer. Sean Russell is founder and chief operating officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | Oct 21, 2026 | $5,115,268of $8.0M target | 37 | $138K | EquityRule 506(b) | Form D ↗ |
| Oct 29, 2025 | Nov 14, 2025 | $3,260,000of $5.0M target | 10 | $326K | EquityRule 506(b) | Form D ↗ |
| Sep 26, 2024 | Oct 15, 2024 | $14,754,032target not set | 43 | $343K | EquityRule 506(b) | Form D ↗ |
| Dec 21, 2023 | Feb 7, 2024 | $950,000of $2.0M target | 10 | $95,000 | Debt, Options, Securities on exercise, Convertible Promissory Notes and WarrantsRule 506(b) | Form D ↗ |
| Aug 12, 2020 | Nov 9, 2021 | $3,500,000fully sold | 5 | $700K | Securities on exerciseRule 506(b) | Form D ↗ |
| Total, five offerings | $27,579,300 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Model Medicines
Model Medicines develops AI-designed drug candidates for human disease. Its platform supports an internal therapeutic pipeline. The investment case depends on whether those candidates keep advancing.
The problem it targets
Model Medicines targets biological choke points, its term for mechanisms that help drive disease. Its premise is that focusing on these mechanisms can yield new drug compounds.
What the product does
The platform uses AI models of chemistry and human biology. Model Medicines turns that work into drug compounds for its development programs.
Progress so far
Model Medicines had named its AI platform GALILEO by April 2025. Daniel Haders II was scheduled to discuss it in New York City on April 2, 2025.
Who backs it
8VC lists Model Medicines as a portfolio company, establishing the venture firm as a backer.
We wrote this summary from public statements by Model Medicines and its investors. It is not investment advice.
Model Medicines in the News
Leadership Team
Executive officers and directors listed on Model Medicines's Form D filed Oct 21, 2026.
Earlier filings also listed Marlon Evans (executive officer and director, last listed Oct 2024) and Kip Quackenbush (executive officer and director, last listed Oct 2024).